Tirzepatide 99.99% High Purity Lyophilized Research Peptide Raw Material, Volume Discount Available
1 Inquiries
1026993-38-3
Industrial Grade
99.99%
10vials/box
2026-09-07
Retatrutide,Tirzepatide,Semaglutide,GHK-CU
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionTestagen peptide known as KEDG is a tetrapeptide consisting of lysine (Lys), glutamic acid (Glu), aspartic acid (Asp), and glycine (Gly), further presented as H–Lys–Glu–Asp–Gly–OH. KEDG represents a bioregulator intended to stimulate and regulate the functions of the endocrine system.[1]Basic Info
-
Product Name:
Testagen
Other Name:Testagen;Testagen (Lys-Glu-Asp-Gly);Glycine, L-lysyl-L-α-glutamyl-L-α-aspartyl-;TESTAGEN 10mg;TESTAGEN 20mg;Lys-Glu-Asp-Gly
CAS No.:1026993-38-3
Molecular Formula:C17H29N5O9
InChIKeys:HKEYFJLTNCUNAD-DCAQKATOSA-N
Molecular Weight:447.44
Categories:
Characteristics-
Density:
1.401±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted)
Boiling Point:990.035±65.00 °C(Press: 760.00 Torr)(predicted)
PKA:3.160±0.10(predicted)
Research-
Class:
Dual agonist — GIPR, GLP-1R
Status:FDA-approved (Mounjaro / Zepbound)
Mechanism:Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. A 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding for extended half-life (~5 days). Selectively activates both GIPR and GLP-1R signaling pathways.
EC50 (Human GLP1R):0.934 nM
EC50 (Human GIPR):0.0224 nM
Source:Frias JP, et al. N Engl J Med. 2021;385(6):503-515.DOI
Clinical Development:NCT03954834; NCT03987919; NCT03882970; NCT03730662; NCT04039503
FDA:Mounjaro, Zepbound (approved 2022-05-13)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Disclaimer:
Tirzepatide is approved as a prescription medicine (Mounjaro, Zepbound) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Retatrutide,Tirzepatide,Semaglutide,GHK-CU
-
Location:
Room 1209, 12th Floor, Unit 1, Building 1, Block A, Shenglong Plaza, No.80 Weiyang Road, Weiyang District, Xi'an City, Shaanxi Province, P.R.China
-
Payment Terms:
TT against copy of documents,D/A,100% TT in advance
-
Average lead Time:
15
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
11-50
-
Year of Establishment:
2025
-
-
Inquiry History1 Inquiries
Country Product Purchase Quantity Date Posted 
United States
Testagen
10 MG May 26, 2026 Post an enquiry for this product